Addus HomeCare (NASDAQ:ADUS) Releases Earnings Results, Beats Expectations By $0.02 EPS

Addus HomeCare (NASDAQ:ADUS) released its earnings results on Monday. The company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.02, Briefing.com reports. The firm had revenue of $289.80 million during the quarter, compared to analyst estimates of $289.42 million. Addus HomeCare had a net margin of 6.18% and a return on equity of 9.81%. The business’s revenue was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.03 EPS.

Addus HomeCare Stock Up 5.5 %

NASDAQ ADUS opened at $130.96 on Thursday. The stock has a market cap of $2.37 billion, a P/E ratio of 29.97, a PEG ratio of 2.29 and a beta of 1.04. Addus HomeCare has a twelve month low of $81.51 and a twelve month high of $136.12. The company’s 50-day simple moving average is $129.75 and its 200 day simple moving average is $120.92.

Wall Street Analysts Forecast Growth

ADUS has been the topic of a number of research analyst reports. Macquarie reaffirmed an “outperform” rating and issued a $139.00 target price on shares of Addus HomeCare in a report on Monday. Oppenheimer raised their price objective on shares of Addus HomeCare from $140.00 to $145.00 and gave the stock an “outperform” rating in a research note on Monday, September 23rd. Stephens upped their target price on shares of Addus HomeCare from $143.00 to $145.00 and gave the company an “overweight” rating in a research note on Wednesday. KeyCorp initiated coverage on shares of Addus HomeCare in a research report on Friday, October 11th. They issued an “overweight” rating and a $150.00 price target on the stock. Finally, Royal Bank of Canada cut their price objective on shares of Addus HomeCare from $141.00 to $136.00 and set an “outperform” rating for the company in a research report on Wednesday. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $131.63.

Insiders Place Their Bets

In other news, EVP Michael D. Wattenbarger sold 21,917 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $133.29, for a total value of $2,921,316.93. Following the completion of the transaction, the executive vice president now directly owns 7,215 shares of the company’s stock, valued at approximately $961,687.35. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Esteban Lopez sold 500 shares of Addus HomeCare stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $130.03, for a total transaction of $65,015.00. Following the completion of the transaction, the director now directly owns 3,866 shares of the company’s stock, valued at $502,695.98. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael D. Wattenbarger sold 21,917 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $133.29, for a total transaction of $2,921,316.93. Following the sale, the executive vice president now directly owns 7,215 shares in the company, valued at $961,687.35. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 22,917 shares of company stock worth $3,050,082 over the last quarter. Company insiders own 4.60% of the company’s stock.

Addus HomeCare Company Profile

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.